ŞBŞule Mine Bakanay

Şule Mine Bakanay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Şule Mine Bakanay has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group

    by Emel Isleyen, Nurcan Alhan, Esra Terzi Demirsoy, Ayfer Geduk, Duygu Nurdan Avci, Mahmut Yeral, Ahmet Burhan Ferhanoglu, Ebru Pekguc, Eren Gunduz, Hava Uskudar Teke, et al.

    Background: Classical Hodgkin lymphoma (cHL) demonstrates high survival rates with the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine); however, the use of bleomycin is associated with a significant risk of pulmonary toxicity. The Risk-Adapted Treatment of HL (RATHL) trial demonstrated that omitting bleomycin in patients with favorable interim Positron Emission Tomography (PET-CT) results did not adversely affect survival outcomes. In this study, we present real-world data from advanced-stage HL patients treated according to the RATHL protocol. Methods: This multicenter, retrospective study included newly diagnosed cHL patients with Ann Arbor stage IIB–IV disease or stage IIA disease with bulky disease or with involvement of three or more sites, enrolled from 29 centers across Türkiye. The analysis focused on patients whose initial treatment was de-escalated from ABVD to AVD (bleomycin was omitted). Data were collected on demographic and clinical prognostic characteristics, interim PET-CT findings (evaluated using the Deauville score), progression-free survival (PFS) and overall survival (OS). Survival outcomes were assessed using Kaplan–Meier analysis. Results: A total of 379 patients were included, with a median age of 34 years (range: 18–78). Following interim PET-CT assessments (After 2 cycles of ABVD), Deauville scores were 1 in 39.8% of patients, 2 in 39.1%, and 3 in 21.1%. Based on these results, bleomycin was omitted immediately after interim PET-CT in 73.9% of patients, after one additional ABVD cycle in 12.1%, and after two additional cycles in 14%. The median follow-up duration was 28 months (range: 6–96). The 3-year PFS and OS rates were 86.0% and 96.1%, respectively. Patients with Deauville scores of 1–2 had a 3-year PFS rate of 87.6%, compared to 79.8% in those with a score of 3 (p = 0.087). Increased age, poor Eastern Cooperative Oncology Group Scale (ECOG) performance status, bulky disease, and higher International Prognostic Scores (IPS) were significantly associated with inferior OS (p < 0.05). There were no significant differences in OS among patients who received 2, 3, or 4 cycles of ABVD. However, among patients treated with 2 cycles of ABVD, both extranodal involvement (p = 0.039) and higher IPS (p = 0.002) were significantly associated with decreased PFS. Conclusions: Our findings demonstrate that PET-guided de-escalation of bleomycin after two cycles of ABVD is feasible, effective, and safe in real-world multicenter practice in Türkiye. The survival outcomes are comparable to those reported in the RATHL study, reinforcing the role of interim PET-CT in guiding individualized therapy. However, patients with high IPS or extranodal involvement may require more tailored management strategies.

  • Open Access

    Prevalence and current management of perianal diseases in patients with acute leukemia

    by Mehmet Gündüz, Şule Mine Bakanay, Samet Yaman, Ahmet Usta, Mehmet Özen, Aysun Şentürk Yıkılmaz, Selin Küçükyurt Kaya, Servihan Doğan, Sema Akıncı, İmdat Dilek

    Tr en Amaç: Perianal enfeksiyon akut lösemi hastalarının sağkalımını tehlikeye atan, morbiditelerini artıran ve yaşam kalitelerini bozan en önemli enfeksiyon nedenlerinden birisidir. Gereç ve Yöntem: Ankara Atatürk Eğitim ve Araştırma Hastanesi Hematoloji Kliniği’nde 2009-2017 arasında akut lösemi nedeniyle standart kemoterapi tedavisi alan 125 hasta geriye dönük olarak çalışmaya alındı. Bulgular: Bu 125 akut lösemi hastasının 25’inde perianal hastalık gelişmiş olup perianal hastalık gelişim riski %20 olarak saptandı. Perianal enfeksiyon ise 13 hastada gelişirken perianal enfeksiyon gelişim riski %10,4 olarak hesaplandı. ALL tanılı hastaların %34’ünde ve AML tanılı hastaların %16’sında perianal hastalık gelişti (p=0,03). Tanıdaki lökosit sayısı 10,000’in üzerinde olanların %29’unda perianal hastalık gelişirken, bu oran lökosit sayısı 10,000’in altında olanlarda %12’de kaldı (p=0,02). ALL hastaları arasında perianal enfeksiyon gelişim riski %21 iken AML hastaları açısından risk %7 olarak saptandı (p=0,04) (Tablo 2). Perianal hastalık gelişen hastaların %64’ünde perianal hastalığın indüksiyon sırasında geri kalanında ise konsolidasyonda geliştiği ortanca gelişme gününün 13 (aralık:1-40) olduğu gözlendi. Perianal hastalık gelişen hastaların %60’ında ateş gözlendiği, %28’inde kan kültüründe üreme olduğu, %16’sında sepsis geliştiği ve %20’sinde ilerleyen dönemde cerrahi tedavi gerektiği gözlendi. Perianal enfeksiyon gelişimi açısından hastalar incelendiğinde ise hastaların %69’unda enfeksiyonun indüksiyon sırasında geliştiği ve ortanca gelişme gününün 17 (aralık:3-34) olduğu gözlendi. Perianal enfeksiyon saptanan hastaların %62’sinde ateş gözlendiği, %46’sında kan kültüründe üreme gözlendiği, hastaların %15’inde sepsis geliştiği ve hastaların %23’ünün ilerleyen dönemde cerrahi tedavi yapıldığı gözlendi. Perianal hastalığı olup kan kültüründe üremesi olan 7 hasta incelendiğinde tüm hastalarda Gram (-) basil ürediği bunların 5’inin Klebsiella pnömonia ve 2’sinin E. coli olduğu gözlendi. Fizik incelemede abse saptanan ve MRG yapılan 6 hasta mevcuttu. Tüm hastalarda MRG’de de abse olduğu gözlendi. Cerrahi girişim yapılan 5 hastaya bakıldığında 3 hastada apse drenajı, 1 hastaya kolostomi açılması yapıldığı, 1 hastaya da polipektomi yapıldığı saptandı. Sonuç: ALL hastalarında AML hastalarına göre daha fazla perianal hastalık ve enfeksiyon geliştiği, perianal hastalığın konservatif tedavi ile büyük oranda düzeltilebileceği ve MRG’nin bu hastaların yönetiminde yol gösterici olabileceği gözlendi. Aim: Perianal infection is one of the most important causes of infection in acute leukemia which puts the life of patients at risk, increases their morbidity and impairs quality of life. Material and Method: At the Ankara Atatürk Training and Research Hospital Hematology Clinic, 125 patients who received standard chemotherapy for acute leukemia between 2009 and 2017 werestudied, retrospectively. Results : Of these 125 acute leukemia patients, 25 (20%) developed perianal disease and 13 (10,4%) developed perianal infection. Perianal disease and infection developed in 34% and 21% of patients with ALL; in 16% and 7% of patients with AML (p=0.03 and p=0.04), respectively. Perianal disease was present in 29% of the patients with a leukocyte count greater than 10,000 at diagnosis, but remained at 12% in those with a leukocyte count below 10,000 (p=0.02). Perianal disease and perianal infection developed in 64% and 69% of the patients during induction and at a median of 13 days (range: 1-40) and 17 days (range: 3-34), respectively. It was observed that 60% of the patients with perianal disease had fever, 28% had positive blood culture, 16% had sepsis and 20% required surgical treatment. Among 7 patients with perianal disease and positive blood cultures, all had Gram (-) bacilli (5 Klebsiella pneumonia and 2 E. coli). Of the 6 patients who had masses in physical examination under went pelvic magnetic resonance imaging (MRI). All patients diagnosed with abscesses on MRI. Five patients who under went surgery; 3 abscess drainage, 1 colostomy and 1 polypectomy was performed. Conclusion: It was observed that perianal disease and infection developed more frequently in ALL patients compared with AML patients; perianal disease could be controlled mainly with conservative treatment and MRI could be an important guide in the management of these patients.

  • Open Access

    Epstein-Barr Virus-Negative Post-Transplant Lymphoproliferative Diseases: Three Distinct Cases from a Single Center

    by Şule Mine Bakanay, Gülşah Kaygusuz, Pervin Topçuoğlu, Şule Şengül, Timur Tunçalı, Kenan Keven, Işınsu Kuzu, Akın Uysal, Mutlu Arat

    Three cases of Epstein-Barr virus (EBV)-negative post-transplant lymphoproliferative disease that occurred 6 to 8 years after renal transplantation are reported. The patients respectively had gastric mucosa-associated lymphoid tissue lymphoma, gastric diffuse large B-cell lymphoma, and atypical Burkitt lymphoma. Absence of EBV in the tissue samples was demonstrated by both in situ hybridization for EBV early RNA and polymerase chain reaction for EBV DNA. Patients were treated with reduction in immunosuppression and combined chemotherapy plus an anti-CD20 monoclonal antibody, rituximab. Despite the reduction in immunosuppression, patients had stable renal functions without loss of graft functions. The patient with atypical Burkitt lymphoma had an abnormal karyotype, did not respond to treatment completely, and died due to disease progression. The other patients are still alive and in remission 5 and 3 years after diagnosis, respectively. EBV-negative post-transplant lymphoproliferative diseases are usually late-onset and are reported to have poor prognosis. Thus, reduction in immunosuppression is usually not sufficient for treatment and more aggressive approaches like rituximab with combined chemotherapy are required.\u